Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B
Chronic hepatitis B (CHB) and liver fibrosis are associated with a high risk of hepatocellular carcinoma (HCC) development. We assessed whether entecavir (ETV) plus Biejia-Ruangan compound (BRC), an anti-fibrotic traditional Chinese medicine, can further reduce the risk of HCC in treatment-naïve Chi...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Ji, Dong [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2022 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
10 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Identification of the antigenic region of - Abdelbaky, Hanan H. ELSEVIER, 2018, official journal of the European Association for the Study of the Liver, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:77 ; year:2022 ; number:6 ; pages:1515-1524 ; extent:10 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.jhep.2022.07.018 |
|---|
| Katalog-ID: |
ELV059502053 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV059502053 | ||
| 003 | DE-627 | ||
| 005 | 20230625013549.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 221219s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jhep.2022.07.018 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001966.pica |
| 035 | |a (DE-627)ELV059502053 | ||
| 035 | |a (ELSEVIER)S0168-8278(22)02982-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.44 |2 bkl | ||
| 100 | 1 | |a Ji, Dong |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B |
| 264 | 1 | |c 2022 | |
| 300 | |a 10 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Chronic hepatitis B (CHB) and liver fibrosis are associated with a high risk of hepatocellular carcinoma (HCC) development. We assessed whether entecavir (ETV) plus Biejia-Ruangan compound (BRC), an anti-fibrotic traditional Chinese medicine, can further reduce the risk of HCC in treatment-naïve Chinese patients with CHB and an Ishak fibrosis score of ≥3 points derived from our parent double-blind randomized placebo-controlled trial. | ||
| 650 | 7 | |a Liver biopsy |2 Elsevier | |
| 650 | 7 | |a Liver stiffness measurement |2 Elsevier | |
| 650 | 7 | |a Long-term outcomes |2 Elsevier | |
| 650 | 7 | |a Traditional Chinese medicine |2 Elsevier | |
| 650 | 7 | |a Hepatitis B virus |2 Elsevier | |
| 650 | 7 | |a Nucleot(s)ide analogs |2 Elsevier | |
| 700 | 1 | |a Chen, Yan |4 oth | |
| 700 | 1 | |a Bi, Jingfeng |4 oth | |
| 700 | 1 | |a Shang, Qinghua |4 oth | |
| 700 | 1 | |a Liu, Huabao |4 oth | |
| 700 | 1 | |a Wang, Jia-Bo |4 oth | |
| 700 | 1 | |a Tan, Lin |4 oth | |
| 700 | 1 | |a Wang, Jing |4 oth | |
| 700 | 1 | |a Chen, Yongping |4 oth | |
| 700 | 1 | |a Li, Qin |4 oth | |
| 700 | 1 | |a Long, Qinghua |4 oth | |
| 700 | 1 | |a Song, Laicheng |4 oth | |
| 700 | 1 | |a Jiang, Li |4 oth | |
| 700 | 1 | |a Xiao, Guangming |4 oth | |
| 700 | 1 | |a Yu, Zujiang |4 oth | |
| 700 | 1 | |a Chen, Liang |4 oth | |
| 700 | 1 | |a Wang, Xiaodong |4 oth | |
| 700 | 1 | |a Chen, Da |4 oth | |
| 700 | 1 | |a Li, Zhiqin |4 oth | |
| 700 | 1 | |a Dong, Zheng |4 oth | |
| 700 | 1 | |a Yang, Yongping |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Abdelbaky, Hanan H. ELSEVIER |t Identification of the antigenic region of |d 2018 |d official journal of the European Association for the Study of the Liver |g Amsterdam [u.a.] |w (DE-627)ELV000433829 |
| 773 | 1 | 8 | |g volume:77 |g year:2022 |g number:6 |g pages:1515-1524 |g extent:10 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.jhep.2022.07.018 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.44 |j Parasitologie |x Medizin |q VZ |
| 951 | |a AR | ||
| 952 | |d 77 |j 2022 |e 6 |h 1515-1524 |g 10 | ||
| author_variant |
d j dj |
|---|---|
| matchkey_str |
jidongchenyanbijingfengshangqinghualiuhu:2022----:neaipubeiragnopudeueteikfeaoellracnmicie |
| hierarchy_sort_str |
2022 |
| bklnumber |
44.44 |
| publishDate |
2022 |
| allfields |
10.1016/j.jhep.2022.07.018 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001966.pica (DE-627)ELV059502053 (ELSEVIER)S0168-8278(22)02982-8 DE-627 ger DE-627 rakwb eng 610 VZ 44.44 bkl Ji, Dong verfasserin aut Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B 2022 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Chronic hepatitis B (CHB) and liver fibrosis are associated with a high risk of hepatocellular carcinoma (HCC) development. We assessed whether entecavir (ETV) plus Biejia-Ruangan compound (BRC), an anti-fibrotic traditional Chinese medicine, can further reduce the risk of HCC in treatment-naïve Chinese patients with CHB and an Ishak fibrosis score of ≥3 points derived from our parent double-blind randomized placebo-controlled trial. Liver biopsy Elsevier Liver stiffness measurement Elsevier Long-term outcomes Elsevier Traditional Chinese medicine Elsevier Hepatitis B virus Elsevier Nucleot(s)ide analogs Elsevier Chen, Yan oth Bi, Jingfeng oth Shang, Qinghua oth Liu, Huabao oth Wang, Jia-Bo oth Tan, Lin oth Wang, Jing oth Chen, Yongping oth Li, Qin oth Long, Qinghua oth Song, Laicheng oth Jiang, Li oth Xiao, Guangming oth Yu, Zujiang oth Chen, Liang oth Wang, Xiaodong oth Chen, Da oth Li, Zhiqin oth Dong, Zheng oth Yang, Yongping oth Enthalten in Elsevier Science Abdelbaky, Hanan H. ELSEVIER Identification of the antigenic region of 2018 official journal of the European Association for the Study of the Liver Amsterdam [u.a.] (DE-627)ELV000433829 volume:77 year:2022 number:6 pages:1515-1524 extent:10 https://doi.org/10.1016/j.jhep.2022.07.018 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.44 Parasitologie Medizin VZ AR 77 2022 6 1515-1524 10 |
| spelling |
10.1016/j.jhep.2022.07.018 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001966.pica (DE-627)ELV059502053 (ELSEVIER)S0168-8278(22)02982-8 DE-627 ger DE-627 rakwb eng 610 VZ 44.44 bkl Ji, Dong verfasserin aut Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B 2022 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Chronic hepatitis B (CHB) and liver fibrosis are associated with a high risk of hepatocellular carcinoma (HCC) development. We assessed whether entecavir (ETV) plus Biejia-Ruangan compound (BRC), an anti-fibrotic traditional Chinese medicine, can further reduce the risk of HCC in treatment-naïve Chinese patients with CHB and an Ishak fibrosis score of ≥3 points derived from our parent double-blind randomized placebo-controlled trial. Liver biopsy Elsevier Liver stiffness measurement Elsevier Long-term outcomes Elsevier Traditional Chinese medicine Elsevier Hepatitis B virus Elsevier Nucleot(s)ide analogs Elsevier Chen, Yan oth Bi, Jingfeng oth Shang, Qinghua oth Liu, Huabao oth Wang, Jia-Bo oth Tan, Lin oth Wang, Jing oth Chen, Yongping oth Li, Qin oth Long, Qinghua oth Song, Laicheng oth Jiang, Li oth Xiao, Guangming oth Yu, Zujiang oth Chen, Liang oth Wang, Xiaodong oth Chen, Da oth Li, Zhiqin oth Dong, Zheng oth Yang, Yongping oth Enthalten in Elsevier Science Abdelbaky, Hanan H. ELSEVIER Identification of the antigenic region of 2018 official journal of the European Association for the Study of the Liver Amsterdam [u.a.] (DE-627)ELV000433829 volume:77 year:2022 number:6 pages:1515-1524 extent:10 https://doi.org/10.1016/j.jhep.2022.07.018 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.44 Parasitologie Medizin VZ AR 77 2022 6 1515-1524 10 |
| allfields_unstemmed |
10.1016/j.jhep.2022.07.018 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001966.pica (DE-627)ELV059502053 (ELSEVIER)S0168-8278(22)02982-8 DE-627 ger DE-627 rakwb eng 610 VZ 44.44 bkl Ji, Dong verfasserin aut Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B 2022 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Chronic hepatitis B (CHB) and liver fibrosis are associated with a high risk of hepatocellular carcinoma (HCC) development. We assessed whether entecavir (ETV) plus Biejia-Ruangan compound (BRC), an anti-fibrotic traditional Chinese medicine, can further reduce the risk of HCC in treatment-naïve Chinese patients with CHB and an Ishak fibrosis score of ≥3 points derived from our parent double-blind randomized placebo-controlled trial. Liver biopsy Elsevier Liver stiffness measurement Elsevier Long-term outcomes Elsevier Traditional Chinese medicine Elsevier Hepatitis B virus Elsevier Nucleot(s)ide analogs Elsevier Chen, Yan oth Bi, Jingfeng oth Shang, Qinghua oth Liu, Huabao oth Wang, Jia-Bo oth Tan, Lin oth Wang, Jing oth Chen, Yongping oth Li, Qin oth Long, Qinghua oth Song, Laicheng oth Jiang, Li oth Xiao, Guangming oth Yu, Zujiang oth Chen, Liang oth Wang, Xiaodong oth Chen, Da oth Li, Zhiqin oth Dong, Zheng oth Yang, Yongping oth Enthalten in Elsevier Science Abdelbaky, Hanan H. ELSEVIER Identification of the antigenic region of 2018 official journal of the European Association for the Study of the Liver Amsterdam [u.a.] (DE-627)ELV000433829 volume:77 year:2022 number:6 pages:1515-1524 extent:10 https://doi.org/10.1016/j.jhep.2022.07.018 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.44 Parasitologie Medizin VZ AR 77 2022 6 1515-1524 10 |
| allfieldsGer |
10.1016/j.jhep.2022.07.018 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001966.pica (DE-627)ELV059502053 (ELSEVIER)S0168-8278(22)02982-8 DE-627 ger DE-627 rakwb eng 610 VZ 44.44 bkl Ji, Dong verfasserin aut Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B 2022 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Chronic hepatitis B (CHB) and liver fibrosis are associated with a high risk of hepatocellular carcinoma (HCC) development. We assessed whether entecavir (ETV) plus Biejia-Ruangan compound (BRC), an anti-fibrotic traditional Chinese medicine, can further reduce the risk of HCC in treatment-naïve Chinese patients with CHB and an Ishak fibrosis score of ≥3 points derived from our parent double-blind randomized placebo-controlled trial. Liver biopsy Elsevier Liver stiffness measurement Elsevier Long-term outcomes Elsevier Traditional Chinese medicine Elsevier Hepatitis B virus Elsevier Nucleot(s)ide analogs Elsevier Chen, Yan oth Bi, Jingfeng oth Shang, Qinghua oth Liu, Huabao oth Wang, Jia-Bo oth Tan, Lin oth Wang, Jing oth Chen, Yongping oth Li, Qin oth Long, Qinghua oth Song, Laicheng oth Jiang, Li oth Xiao, Guangming oth Yu, Zujiang oth Chen, Liang oth Wang, Xiaodong oth Chen, Da oth Li, Zhiqin oth Dong, Zheng oth Yang, Yongping oth Enthalten in Elsevier Science Abdelbaky, Hanan H. ELSEVIER Identification of the antigenic region of 2018 official journal of the European Association for the Study of the Liver Amsterdam [u.a.] (DE-627)ELV000433829 volume:77 year:2022 number:6 pages:1515-1524 extent:10 https://doi.org/10.1016/j.jhep.2022.07.018 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.44 Parasitologie Medizin VZ AR 77 2022 6 1515-1524 10 |
| allfieldsSound |
10.1016/j.jhep.2022.07.018 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001966.pica (DE-627)ELV059502053 (ELSEVIER)S0168-8278(22)02982-8 DE-627 ger DE-627 rakwb eng 610 VZ 44.44 bkl Ji, Dong verfasserin aut Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B 2022 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Chronic hepatitis B (CHB) and liver fibrosis are associated with a high risk of hepatocellular carcinoma (HCC) development. We assessed whether entecavir (ETV) plus Biejia-Ruangan compound (BRC), an anti-fibrotic traditional Chinese medicine, can further reduce the risk of HCC in treatment-naïve Chinese patients with CHB and an Ishak fibrosis score of ≥3 points derived from our parent double-blind randomized placebo-controlled trial. Liver biopsy Elsevier Liver stiffness measurement Elsevier Long-term outcomes Elsevier Traditional Chinese medicine Elsevier Hepatitis B virus Elsevier Nucleot(s)ide analogs Elsevier Chen, Yan oth Bi, Jingfeng oth Shang, Qinghua oth Liu, Huabao oth Wang, Jia-Bo oth Tan, Lin oth Wang, Jing oth Chen, Yongping oth Li, Qin oth Long, Qinghua oth Song, Laicheng oth Jiang, Li oth Xiao, Guangming oth Yu, Zujiang oth Chen, Liang oth Wang, Xiaodong oth Chen, Da oth Li, Zhiqin oth Dong, Zheng oth Yang, Yongping oth Enthalten in Elsevier Science Abdelbaky, Hanan H. ELSEVIER Identification of the antigenic region of 2018 official journal of the European Association for the Study of the Liver Amsterdam [u.a.] (DE-627)ELV000433829 volume:77 year:2022 number:6 pages:1515-1524 extent:10 https://doi.org/10.1016/j.jhep.2022.07.018 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.44 Parasitologie Medizin VZ AR 77 2022 6 1515-1524 10 |
| language |
English |
| source |
Enthalten in Identification of the antigenic region of Amsterdam [u.a.] volume:77 year:2022 number:6 pages:1515-1524 extent:10 |
| sourceStr |
Enthalten in Identification of the antigenic region of Amsterdam [u.a.] volume:77 year:2022 number:6 pages:1515-1524 extent:10 |
| format_phy_str_mv |
Article |
| bklname |
Parasitologie |
| institution |
findex.gbv.de |
| topic_facet |
Liver biopsy Liver stiffness measurement Long-term outcomes Traditional Chinese medicine Hepatitis B virus Nucleot(s)ide analogs |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Identification of the antigenic region of |
| authorswithroles_txt_mv |
Ji, Dong @@aut@@ Chen, Yan @@oth@@ Bi, Jingfeng @@oth@@ Shang, Qinghua @@oth@@ Liu, Huabao @@oth@@ Wang, Jia-Bo @@oth@@ Tan, Lin @@oth@@ Wang, Jing @@oth@@ Chen, Yongping @@oth@@ Li, Qin @@oth@@ Long, Qinghua @@oth@@ Song, Laicheng @@oth@@ Jiang, Li @@oth@@ Xiao, Guangming @@oth@@ Yu, Zujiang @@oth@@ Chen, Liang @@oth@@ Wang, Xiaodong @@oth@@ Chen, Da @@oth@@ Li, Zhiqin @@oth@@ Dong, Zheng @@oth@@ Yang, Yongping @@oth@@ |
| publishDateDaySort_date |
2022-01-01T00:00:00Z |
| hierarchy_top_id |
ELV000433829 |
| dewey-sort |
3610 |
| id |
ELV059502053 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV059502053</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625013549.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">221219s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jhep.2022.07.018</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001966.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV059502053</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0168-8278(22)02982-8</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.44</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Ji, Dong</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">10</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Chronic hepatitis B (CHB) and liver fibrosis are associated with a high risk of hepatocellular carcinoma (HCC) development. We assessed whether entecavir (ETV) plus Biejia-Ruangan compound (BRC), an anti-fibrotic traditional Chinese medicine, can further reduce the risk of HCC in treatment-naïve Chinese patients with CHB and an Ishak fibrosis score of ≥3 points derived from our parent double-blind randomized placebo-controlled trial.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Liver biopsy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Liver stiffness measurement</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Long-term outcomes</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Traditional Chinese medicine</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Hepatitis B virus</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Nucleot(s)ide analogs</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chen, Yan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bi, Jingfeng</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shang, Qinghua</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Liu, Huabao</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wang, Jia-Bo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tan, Lin</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wang, Jing</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chen, Yongping</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Li, Qin</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Long, Qinghua</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Song, Laicheng</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jiang, Li</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Xiao, Guangming</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yu, Zujiang</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chen, Liang</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wang, Xiaodong</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chen, Da</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Li, Zhiqin</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dong, Zheng</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yang, Yongping</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Abdelbaky, Hanan H. ELSEVIER</subfield><subfield code="t">Identification of the antigenic region of</subfield><subfield code="d">2018</subfield><subfield code="d">official journal of the European Association for the Study of the Liver</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000433829</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:77</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:6</subfield><subfield code="g">pages:1515-1524</subfield><subfield code="g">extent:10</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jhep.2022.07.018</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.44</subfield><subfield code="j">Parasitologie</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">77</subfield><subfield code="j">2022</subfield><subfield code="e">6</subfield><subfield code="h">1515-1524</subfield><subfield code="g">10</subfield></datafield></record></collection>
|
| author |
Ji, Dong |
| spellingShingle |
Ji, Dong ddc 610 bkl 44.44 Elsevier Liver biopsy Elsevier Liver stiffness measurement Elsevier Long-term outcomes Elsevier Traditional Chinese medicine Elsevier Hepatitis B virus Elsevier Nucleot(s)ide analogs Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B |
| authorStr |
Ji, Dong |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV000433829 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 VZ 44.44 bkl Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B Liver biopsy Elsevier Liver stiffness measurement Elsevier Long-term outcomes Elsevier Traditional Chinese medicine Elsevier Hepatitis B virus Elsevier Nucleot(s)ide analogs Elsevier |
| topic |
ddc 610 bkl 44.44 Elsevier Liver biopsy Elsevier Liver stiffness measurement Elsevier Long-term outcomes Elsevier Traditional Chinese medicine Elsevier Hepatitis B virus Elsevier Nucleot(s)ide analogs |
| topic_unstemmed |
ddc 610 bkl 44.44 Elsevier Liver biopsy Elsevier Liver stiffness measurement Elsevier Long-term outcomes Elsevier Traditional Chinese medicine Elsevier Hepatitis B virus Elsevier Nucleot(s)ide analogs |
| topic_browse |
ddc 610 bkl 44.44 Elsevier Liver biopsy Elsevier Liver stiffness measurement Elsevier Long-term outcomes Elsevier Traditional Chinese medicine Elsevier Hepatitis B virus Elsevier Nucleot(s)ide analogs |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
y c yc j b jb q s qs h l hl j b w jbw l t lt j w jw y c yc q l ql q l ql l s ls l j lj g x gx z y zy l c lc x w xw d c dc z l zl z d zd y y yy |
| hierarchy_parent_title |
Identification of the antigenic region of |
| hierarchy_parent_id |
ELV000433829 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Identification of the antigenic region of |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV000433829 |
| title |
Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B |
| ctrlnum |
(DE-627)ELV059502053 (ELSEVIER)S0168-8278(22)02982-8 |
| title_full |
Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B |
| author_sort |
Ji, Dong |
| journal |
Identification of the antigenic region of |
| journalStr |
Identification of the antigenic region of |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2022 |
| contenttype_str_mv |
zzz |
| container_start_page |
1515 |
| author_browse |
Ji, Dong |
| container_volume |
77 |
| physical |
10 |
| class |
610 VZ 44.44 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Ji, Dong |
| doi_str_mv |
10.1016/j.jhep.2022.07.018 |
| dewey-full |
610 |
| title_sort |
entecavir plus biejia-ruangan compound reduces the risk of hepatocellular carcinoma in chinese patients with chronic hepatitis b |
| title_auth |
Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B |
| abstract |
Chronic hepatitis B (CHB) and liver fibrosis are associated with a high risk of hepatocellular carcinoma (HCC) development. We assessed whether entecavir (ETV) plus Biejia-Ruangan compound (BRC), an anti-fibrotic traditional Chinese medicine, can further reduce the risk of HCC in treatment-naïve Chinese patients with CHB and an Ishak fibrosis score of ≥3 points derived from our parent double-blind randomized placebo-controlled trial. |
| abstractGer |
Chronic hepatitis B (CHB) and liver fibrosis are associated with a high risk of hepatocellular carcinoma (HCC) development. We assessed whether entecavir (ETV) plus Biejia-Ruangan compound (BRC), an anti-fibrotic traditional Chinese medicine, can further reduce the risk of HCC in treatment-naïve Chinese patients with CHB and an Ishak fibrosis score of ≥3 points derived from our parent double-blind randomized placebo-controlled trial. |
| abstract_unstemmed |
Chronic hepatitis B (CHB) and liver fibrosis are associated with a high risk of hepatocellular carcinoma (HCC) development. We assessed whether entecavir (ETV) plus Biejia-Ruangan compound (BRC), an anti-fibrotic traditional Chinese medicine, can further reduce the risk of HCC in treatment-naïve Chinese patients with CHB and an Ishak fibrosis score of ≥3 points derived from our parent double-blind randomized placebo-controlled trial. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| container_issue |
6 |
| title_short |
Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B |
| url |
https://doi.org/10.1016/j.jhep.2022.07.018 |
| remote_bool |
true |
| author2 |
Chen, Yan Bi, Jingfeng Shang, Qinghua Liu, Huabao Wang, Jia-Bo Tan, Lin Wang, Jing Chen, Yongping Li, Qin Long, Qinghua Song, Laicheng Jiang, Li Xiao, Guangming Yu, Zujiang Chen, Liang Wang, Xiaodong Chen, Da Li, Zhiqin Dong, Zheng Yang, Yongping |
| author2Str |
Chen, Yan Bi, Jingfeng Shang, Qinghua Liu, Huabao Wang, Jia-Bo Tan, Lin Wang, Jing Chen, Yongping Li, Qin Long, Qinghua Song, Laicheng Jiang, Li Xiao, Guangming Yu, Zujiang Chen, Liang Wang, Xiaodong Chen, Da Li, Zhiqin Dong, Zheng Yang, Yongping |
| ppnlink |
ELV000433829 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.jhep.2022.07.018 |
| up_date |
2024-07-06T22:11:46.417Z |
| _version_ |
1803869388976160768 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV059502053</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625013549.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">221219s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jhep.2022.07.018</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001966.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV059502053</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0168-8278(22)02982-8</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.44</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Ji, Dong</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">10</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Chronic hepatitis B (CHB) and liver fibrosis are associated with a high risk of hepatocellular carcinoma (HCC) development. We assessed whether entecavir (ETV) plus Biejia-Ruangan compound (BRC), an anti-fibrotic traditional Chinese medicine, can further reduce the risk of HCC in treatment-naïve Chinese patients with CHB and an Ishak fibrosis score of ≥3 points derived from our parent double-blind randomized placebo-controlled trial.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Liver biopsy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Liver stiffness measurement</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Long-term outcomes</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Traditional Chinese medicine</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Hepatitis B virus</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Nucleot(s)ide analogs</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chen, Yan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bi, Jingfeng</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shang, Qinghua</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Liu, Huabao</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wang, Jia-Bo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tan, Lin</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wang, Jing</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chen, Yongping</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Li, Qin</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Long, Qinghua</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Song, Laicheng</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jiang, Li</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Xiao, Guangming</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yu, Zujiang</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chen, Liang</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wang, Xiaodong</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chen, Da</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Li, Zhiqin</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dong, Zheng</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yang, Yongping</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Abdelbaky, Hanan H. ELSEVIER</subfield><subfield code="t">Identification of the antigenic region of</subfield><subfield code="d">2018</subfield><subfield code="d">official journal of the European Association for the Study of the Liver</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000433829</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:77</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:6</subfield><subfield code="g">pages:1515-1524</subfield><subfield code="g">extent:10</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jhep.2022.07.018</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.44</subfield><subfield code="j">Parasitologie</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">77</subfield><subfield code="j">2022</subfield><subfield code="e">6</subfield><subfield code="h">1515-1524</subfield><subfield code="g">10</subfield></datafield></record></collection>
|
| score |
7.400899 |